Spots Global Cancer Trial Database for primary systemic amyloidosis
Every month we try and update this database with for primary systemic amyloidosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | NCT00564889 | Multiple Myelom... | cyclophosphamid... dexamethasone lenalidomide | 18 Years - | Mayo Clinic | |
| Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | NCT00030381 | Primary Systemi... | 4'-iodo-4'-deox... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | NCT00075608 | Multiple Myelom... Plasma Cell Neo... | filgrastim melphalan autologous stem... stem cell infus... | 18 Years - 65 Years | Boston Medical Center | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00004165 | Multiple Myelom... | filgrastim melphalan peripheral bloo... | - | Northwestern University | |
| Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | NCT00679367 | Multiple Myelom... | dexamethasone lenalidomide melphalan | 18 Years - | Boston Medical Center | |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | NCT00007995 | Multiple Myelom... | filgrastim recombinant int... sargramostim busulfan cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial | NCT02207556 | Primary Systemi... | Doxycycline | 18 Years - | Medical College of Wisconsin | |
| CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | NCT00091260 | Multiple Myelom... | dexamethasone lenalidomide | 18 Years - | Boston Medical Center | |
| Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed | NCT01194791 | Primary Systemi... | Lenalidomide Cyclophosphamid... Dexamethasone | 18 Years - | PETHEMA Foundation | |
| Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | NCT00547365 | Multiple Myelom... Plasma Cell Neo... | Human immune gl... | 18 Years - | University of Tennessee | |
| S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis | NCT00002849 | Multiple Myelom... | recombinant int... dexamethasone | 18 Years - | SWOG Cancer Research Network | |
| 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis | NCT00003853 | Multiple Myelom... | 4'-iodo-4'-deox... | 18 Years - | National Cancer Institute (NCI) | |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | NCT00919139 | Multiple Myelom... Smoldering Myel... Waldenstrom's M... Monoclonal Gamm... Amyloidosis | biologic sample... | - | SWOG Cancer Research Network | |
| Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis | NCT01072773 | Primary Systemi... | bortezomib cyclophosphamid... dexamethasone | 18 Years - | Mayo Clinic | |
| PS-341 in Treating Patients With Advanced Cancer | NCT00006362 | Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu... | bortezomib | 18 Years - | Mayo Clinic | |
| Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | NCT00790647 | Multiple Myelom... | filgrastim bortezomib melphalan Stem Cell Infus... | 18 Years - 65 Years | Boston Medical Center | |
| Collection of Samples and Clinical Data From Patients With Amyloid Diseases | NCT00898235 | Multiple Myelom... | clonality analy... polymerase chai... protein analysi... biologic sample... laboratory biom... fluorescence sp... quality-of-life... | 18 Years - | Boston Medical Center | |
| Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis | NCT00075621 | Multiple Myelom... | filgrastim melphalan autologous peri... | 18 Years - 65 Years | Boston Medical Center | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | NCT01728259 | Light Chain Dep... Primary Systemi... | pomalidomide bortezomib dexamethasone Laboratory Biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis | NCT03499808 | Amorphous, Eosi... Constipation Diarrhea Early Satiety Gastrointestina... Hepatomegaly Lymphadenopathy Macroglossia Nausea Primary Systemi... Purpura Recurrent Prima... Refractory Prim... | Isatuximab Laboratory Biom... | 18 Years - | SWOG Cancer Research Network | |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | NCT01849783 | Extramedullary ... Isolated Plasma... Light Chain Dep... Primary Systemi... Stage I Multipl... Stage II Multip... Stage III Multi... | dexamethasone cisplatin doxorubicin cyclophosphamid... etoposide bortezomib thalidomide melphalan autologous stem... | 65 Years - 85 Years | University of Iowa | |
| Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | NCT01849783 | Extramedullary ... Isolated Plasma... Light Chain Dep... Primary Systemi... Stage I Multipl... Stage II Multip... Stage III Multi... | dexamethasone cisplatin doxorubicin cyclophosphamid... etoposide bortezomib thalidomide melphalan autologous stem... | 65 Years - 85 Years | University of Iowa | |
| S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis | NCT00064337 | Multiple Myelom... Plasma Cell Mye... | filgrastim cyclophosphamid... dexamethasone melphalan thalidomide peripheral bloo... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis | NCT00458822 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis | NCT00089167 | Multiple Myelom... | filgrastim dexamethasone melphalan thalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | NCT00477971 | Multiple Myelom... | filgrastim dexamethasone melphalan autologous hema... | 18 Years - | Mayo Clinic | |
| S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. | NCT00919139 | Multiple Myelom... Smoldering Myel... Waldenstrom's M... Monoclonal Gamm... Amyloidosis | biologic sample... | - | SWOG Cancer Research Network | |
| Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis | NCT01078454 | Light Chain Dep... Primary Systemi... | melphalan dexamethasone bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | NCT00007995 | Multiple Myelom... | filgrastim recombinant int... sargramostim busulfan cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis | NCT00224393 | Primary Systemi... | Enbrel | 18 Years - | The Cleveland Clinic | |
| Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | NCT00477971 | Multiple Myelom... | filgrastim dexamethasone melphalan autologous hema... | 18 Years - | Mayo Clinic | |
| Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis | NCT00458822 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis | NCT00224393 | Primary Systemi... | Enbrel | 18 Years - | The Cleveland Clinic | |
| S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis | NCT00002849 | Multiple Myelom... | recombinant int... dexamethasone | 18 Years - | SWOG Cancer Research Network | |
| Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis | NCT00458822 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | NCT00679367 | Multiple Myelom... | dexamethasone lenalidomide melphalan | 18 Years - | Boston Medical Center | |
| Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | NCT00564889 | Multiple Myelom... | cyclophosphamid... dexamethasone lenalidomide | 18 Years - | Mayo Clinic | |
| 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | NCT00075608 | Multiple Myelom... Plasma Cell Neo... | filgrastim melphalan autologous stem... stem cell infus... | 18 Years - 65 Years | Boston Medical Center | |
| Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation | NCT00052884 | Drug/Agent Toxi... Multiple Myelom... | filgrastim amifostine trih... melphalan bone marrow abl... peripheral bloo... | 18 Years - 70 Years | Eastern Cooperative Oncology Group | |
| Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease | NCT00520767 | Primary Systemi... Light Chain Dep... | bortezomib dexamethasone melphalan microarray anal... flow cytometry laboratory biom... quality-of-life... | 18 Years - 120 Years | Barbara Ann Karmanos Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
